Prospective four years of evaluation of erectile function after low-dose-rate prostate brachytherapy using baseline IIEF-5 > 16
| Autor: | Jean-Baptiste Coquet, Antoine Valeri, Georges Fournier, Ulrike Schick, nadja schoentgen, F. Delage, S. Serey-eiffel, Olivier Pradier, Julien Marolleau, Pierre Callerot, Alexandre Fourcade, J.-P. Malhaire |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0106 biological sciences
medicine.medical_specialty erectile dysfunction medicine.medical_treatment Brachytherapy brachytherapy Urology lcsh:Medicine iief-5 01 natural sciences radiation therapy Prostate cancer Prostate Medicine Radiology Nuclear Medicine and imaging Low dose rate Original Paper business.industry 010401 analytical chemistry lcsh:R Erectile function medicine.disease prostate cancer 0104 chemical sciences Radiation therapy Erectile dysfunction medicine.anatomical_structure Oncology business Prostate brachytherapy 010606 plant biology & botany |
| Zdroj: | Journal of Contemporary Brachytherapy, Vol 11, Iss 3, Pp 195-200 (2019) Journal of Contemporary Brachytherapy |
| ISSN: | 2081-2841 |
| Popis: | Purpose Prostate brachytherapy (BT) is a validated treatment for localized prostate cancer (CaP) and an attractive therapy option for patients seeking to preserve erectile function (EF). The aim of this paper is to prospectively assess EF evolution during 4 years after BT. Material and methods Between February 2007 and July 2012, 179 patients underwent an exclusive Iodine-125 BT, for low-intermediate favorable risk CaP of whom, 102 had an initial international index of erectile function 5 score (IIEF-5) > 16 and were included in the study. Of those, 12.7% received neo-adjuvant hormonotherapy (HT) to decrease the prostate volume. Post-BT intake of phosphodiesterase inhibitors (PDE5i) was not an exclusion criterion. Erectile function was prospectively assessed using a validated questionnaire IIEF-5 before treatment and annually for 4 years. Results At 1-year follow-up, 54% of patients preserved an IIEF-5 > 16 and only 8% suffered from severe ED. During the next 3 years, the results were not statistically different. The mean IIEF-5 lost 4 points during the first year, 17 vs. 21, and remained stable during the following 3 years. We did not find any significant differences in the proportion of patients treated by PDE5i (18-20%). As for patients with a normal preoperative IIEF-5 (> 21) (n = 52), 35-42% preserved a normal EF and 71-77% maintained an IIEF-5 > 16, including 13-19% of patients who needed PDE5i. Those results were stable for over 4 years. Conclusions During the first 4 years after BT, more than half of patients maintained an IIEF-5 > 16, and EF results remained stable. Severe erectile dysfunction (ED) was very rare. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|